A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

Phase 2 Completed 82 enrolled Embera NeuroTherapeutics, Inc. National Institute on Drug Abuse (NIDA) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD).

Timeline

Start: 2020-07-29
Primary completion: 2022-07-27
Completion: 2022-10-15

Publications

Background Kablinger AS, Lindner MA, Casso S, Hefti F, DeMuth G, Fox BS, McNair LA, McCarthy BG, Goeders NE. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study. J Psychopharmacol. 2012 Jul;26(7):973-81. doi: 10.1177/0269881111430745. Epub 2012 Jan 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metyrapone	Small molecule	720 mg	Oral
Subject	oxazepam	Small molecule	24 mg	Oral

A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

Summary

Timeline

Publications

Drugs

Indications